SCHEMBL4560494

SCHEMBL4560494

O=C(NCc1ccc(Cl)c(Cl)c1)N1CCC1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.72
EPHX2 P34913 1/20 0.69
KMT2A Q03164 6/20 0.59
MEN1 O00255 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 3/20 0.59
HTT P42858 1/20 0.59
RECQL P46063 1/20 0.59
TSHR P16473 2/20 0.56
ERN1 O75460 1/20 0.54
P2RY12 Q9H244 1/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 2/20 0.50
POLB P06746 1/20 0.50
FAAH O00519 1/20 0.49
HPGD P15428 1/20 0.49
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443674 0.87 HRH3 (0.74) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL12655872 0.86 HRH3 (0.69) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL14413613 0.86 HRH3 (0.70) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL5466723 0.85 HRH3 (0.71) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL12655777 0.84 MAPT (0.58) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL5466560 0.84 HRH3 (1.00) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL12655881 0.84 HRH3 (0.66) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL12655412 0.83 FAAH (0.70) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL13873318 0.82 EPHX2 (1.00) HRH3EPHX2KMT2AMEN1SMN1; SMN2
SCHEMBL12655415 0.82 HRH3 (0.67) HRH3EPHX2KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B HRH3 4094/4885EPHX2 2459/4885KMT2A 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.